未登录

A

Anita K. Dunbier

University of Otago

H指数:25

被引数:4,300

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of immunocompetent models for primary and metastatic ER plus breast cancer

开发原发性及转移性ER阳性乳腺癌的免疫活性模型

Animal Models and Experimental Medicine

IF3.4

2026-05-010

OAAI

Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer

BREAST CANCER RESEARCH

IF5.6

2021-10-035

OAAI

Increased gene expression variability in BRCA1-associated and basal-like breast tumours

BREAST CANCER RESEARCH AND TREATMENT

IF3

2021-07-213

OAAI

Variable expression quantitative trait loci analysis of breast cancer risk variants

SCIENTIFIC REPORTS

IF3.9

2021-03-307

OAAI

Investigation of combination treatment an aromatase inhibitor and anti-inflammatory treatment in a model of oestrogen receptor positive breast cancer

CANCER RESEARCH

IF16.6

2020-02-150

PRE

Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1

SCIENCE SIGNALING

IF6.6

2018-09-2551

OAAI

Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers

IF3.4

2018-08-0964

OAAI

A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse

CLINICAL CANCER RESEARCH

IF10.2

2017-06-1433

OAAI

4CSeq analysis of a breast cancer susceptibility locus on 6q25.1

CANCER RESEARCH

IF16.6

2016-07-150

PRE

Development for clinical utility of a validated predictive test of clinical response to aromatase inhibitors

CANCER RESEARCH

IF16.6

2015-05-010

PRE

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer

BREAST CANCER RESEARCH

IF5.6

2015-03-119

OAAI

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers

BREAST CANCER RESEARCH

IF5.6

2014-10-3127

OAAI

Expression of genes spanning a breast cancer susceptibility locus on 6q25.1 is modulated by epigenetic modification

CANCER RESEARCH

IF16.6

2014-10-010

PRE

Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

CLINICAL CANCER RESEARCH

IF10.2

2014-07-3120

OAAI

Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor-Positive Breast Cancer and Their Relationship with Antiproliferative Response

CLINICAL CANCER RESEARCH

IF10.2

2014-04-3035

OAAI

Accurate and robust prediction of clinical response to aromatase inhibitors by two weeks of neoadjuvant breast cancer treatment

CANCER RESEARCH

IF16.6

2013-12-150

PRE

Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

CLINICAL CANCER RESEARCH

IF10.2

2013-05-12116

OAAI

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

BREAST CANCER RESEARCH

IF5.6

2012-05-1841

OAAI

ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

CANCER DISCOVERY

IF33.3

2011-09-14292

OAAI

Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation

CLINICAL CANCER RESEARCH

IF10.2

2011-07-3159

OAAI